Misoprostol is a synthetic prostaglandin E1 analogue that has gastric antisecretory, mucosal protective and uterine contractibility properties. The antisecretory activity and uterine contractibility of Misoprostol is mediated through a class of high affinity E- type prostaglandin receptors on the surface of gastric parietal cells and uterus respectively. Misoprostol achieves cytoprotection by stimulation of gastric mucus secretion, duodenal bicarbonate secretion and gastric mucosal blood flow.
Cytomis Tablet 100 mcg
Gastric and duodenal ulcers, NSAID-associated ulceration: 800 mcg daily in 2-4 divided doses for at least 4 wk even if symptoms are relieved sooner, may continue up to 8 wk if needed. Further courses may be given if the ulcer relapses.
Prophylaxis of NSAID-induced ulcers: 200 mcg 2-4 times daily; if not tolerated, may reduce dose to 100 mcg 4 times daily.
Gynecological dosage & administration-
Induction of Labor: 25 mcg vaginally 6 hourly or, 50 mcg orally 4 hourly.
Postpartum Hemorrhage (PPH) prophylaxis: 400 mcg to 600 mcg orally or rectally immediately following delivery of the child.
Postpartum Hemorrhage (PPH) treatment: 1,000 mcg rectally or, 200 mcg orally with 400 mcg sublingually
Termination of pregnancy (49 days or less duration): 400 mcg as a single dose, given 36-48 hr after mifepristone.